Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Investor Presentation (May 2023)
15 slides from Vivoryon Therapeutics's investor presentation, May 2023
Slide 1: Upstream intervention to address multiple hallmarks of AD
Upstream intervention to address multiple hallmarks of AD Tackling AD at the roots |Vivoryon Therapeutics N.V. – May 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Investment Highlights
Investment Highlights Late-Stage Lead Program Varoglutamstat Approach ◆ DIFFERENTIATED UPSTREAM APPROACH TO ALZHEIMER’S DISEASE treatment targeting ◆ PURPOSE-BUILT PIPELINE of small major hallmarks of disease with proven early molecules addressing medical need in signs of disease-modifying activity:
Slide 4: Overcoming Challenges in Alzheimer's Disease – Our Solution
Overcoming Challenges in Alzheimer’s Disease – Our Solution ONGOING CHALLENGES IN AD VIVORYON’S APPROACH Discovered QPCT-mediated formation of a ~30 million people worldwide and expected to double by 2050, with neurotoxic Abeta variant, N3pE-Abeta (pGlu-Abeta), ~12.7 million in the US alone as drive
Slide 5: Lead Product Candidate: Varoglutamstat Prevents N3pE-formation in AD
Lead Product Candidate: Varoglutamstat Prevents N3pE-formation in AD ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS Increased activity of glutaminyl cyclase (QPCT) is Abeta CCL2 associated with AD pathology in humans1 upregulated in AD QPCT catalyzes formation of neuroto
Slide 6: Varoglutamstat Clinical Development Strategy
Varoglutamstat Clinical Development Strategy Clear Path To Potential Regulatory Approval Based on Well-Informed, Extensive Phase 1 and Phase 2 Trials Pivotal study or Phase 2b VIVIAD Assessment of safety, tolerability and accelerated approval efficacy in 250 patients with MCI or FDA Fast Track desig
Slide 7: Phase 2b Study
Phase 2b Study Ongoing Assessment of Safety, Tolerability and Efficacy of Varoglutamstat in Patients with MCI and Mild AD1,2 Site visits 4 12 16 24 INTERIM SAFETY 36 48 60 72 84-96 FINAL DATA Mid-22 1Q24 w 13-24 FIRST 90 PATIENTS 1:1:1 w 25–48/96 Placebo / 300 mg / 600 mg DSMB DECISION ALL PATIENTS
Slide 8: Recruitment and Safety Update
Recruitment and Safety Update ◆ DSMB/June 2022: Safety assessment after 90th patient had reached week 24; led to selection of 600 mg, the highest well-tolerated dose, as dose for the remainder of the study ◆ No assessment of efficacy ◆ Recruitment completed with a global screening failure rate of le
Slide 9: VIVIAD Data Suggest Favorable Safety Profile
VIVIAD Data Suggest Favorable Safety Profile TREATMENT EMERGENT ADVERSE TEAEs BY SOC N (%) EVENTS OBSERVED = OR > 5 (AS OF OCT 07, 2022) Covid 19 infection 40 (18) Diarrhea 14 (6) Headache 13 (6) Nausea 13 (6) Depression 13 (6) Fatigue 12 (5) Constipation 10 (4) Rash 9 (4) Night sweats 7 (3) Dizzine
Slide 10: Phase 2 Study with Option to Expand to Phase 3
Phase 2 Study with Option to Expand to Phase 3 START Site visits 4 8 12 16 24 36 48 60 72 2H21 w 1-24 PHASE 2 PHASE 2 ADAPTIVE DOSE FINDING ONGOING w 25 – 72 TREATMENT 180 patients 180 patients ENDPOINTS Placebo / 600 mg / 300 mg / 150 mg Placebo / selected dose 1:1 Primary efficacy: (all BID) (all
Slide 11: Multiple Avenues to Value Generation
Multiple Avenues to Value Generation Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER’S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL
Slide 12: Diverse Pipeline Addressing Severe Diseases
Diverse Pipeline Addressing Severe Diseases Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Status Varoglutamstat SMI (PQ912) VIVIAD - Ph2b in EU Fully recruited; Final readout Q1/2024 QPCT/L Varoglutamstat SMI Ph 2a ongoing; expanded treatment (PQ912) VIVA-MIND - Ph2a/b in
Slide 13: Experienced Leadership
Experienced Leadership Seasoned Biopharma Experts Covering All Relevant Aspects of Drug Development EXECUTIVE DIRECTORS NON-EXECUTIVE DIRECTORS Ulrich Dauer, PhD Erich Platzer, MD Chief Executive Officer, Executive Director Chairman Dinnies Johannes von der Osten, PhD Vice Chairman Charlotte Lohmann
Slide 14: Positioned for Continued Value Generation
Positioned for Continued Value Generation Varoglutamstat: Differentiated Phase 2 Catalysts and Future Opportunities Asset with Unique Potential in AD ◆ UPCOMING CATALYSTS: ◆ STATISTICALLY SIGNIFICANT changes in working memory ◆ VIVIAD European Phase 2b: Final readout Q1/2024 ◆ CONVENIENT ADMINISTRAT
Slide 15: Vivoryon Therapeutics N.V. contact details
Vivoryon Therapeutics N.V. Munich Franz-Josef-Delonge-Str. 5 81249 München Germany Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Investor Presentation (May 2023) on 6ix